We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stomach Cancer Bacterium Increases Colorectal Cancer Risk

By LabMedica International staff writers
Posted on 24 Oct 2018
Print article
Image: Immunohistochemistry staining of Helicobacter pylori on Formalin-Fixed Paraffin-Embedded (FFPE) Infected Stomach Tissue (Photo courtesy of Bio SB).
Image: Immunohistochemistry staining of Helicobacter pylori on Formalin-Fixed Paraffin-Embedded (FFPE) Infected Stomach Tissue (Photo courtesy of Bio SB).
A bacterium known for causing stomach cancer might also increase the risk of certain colorectal cancers, particularly among African Americans. An association of the bacteria Helicobacter pylori, the primary cause of gastric cancer, and risk of colorectal cancer (CRC) have been reported.

H. pylori is a common type of bacteria that grows in the digestive tract and has a tendency to attack the stomach lining. It infects the stomachs of roughly 60% of the world’s adult population. H. pylori infections are usually harmless, but they are responsible for the majority of ulcers in the stomach and small intestine.

A large team of scientists associated with the Duke University Medical Center (Durham, NC, USA) used H. pylori multiplex serologic assays to analyze serum samples from 4,063 incident cases of CRC, collected before diagnosis, and 4,063 matched individuals without CRC (controls) from 10 prospective cohorts for antibody responses to 13 H. pylori proteins, including virulence factors Vacuolating Cytotoxin A (VacA) and Cytotoxin-associated A (CagA). The association of sero-positivity to H. pylori proteins, as well as protein-specific antibody level, with odds of CRC was determined by conditional logistic regression.

The team found that found that H. pylori infections were equally common in both the cancer and non-cancer group, with 4 in 10 patients in both groups testing positive for exposure to the bacterium. However stark racial differences also appeared as white patients had below average H. pylori infection rates, and Asian Americans had average rates. For black and Latino patients, however, the rates were much higher. Among African Americans, 65% of the non-cancer patients and 71% of the colorectal cancer patients had H. pylori antibodies; among Latinos, 77% of the non-cancer group and 74% of the cancer group had antibodies.

Further analysis showed that antibodies to four H. pylori proteins were most often present among the different ethnic groups with colorectal cancer. One H. pylori protein in particular, VacA, had the strongest association with increased odds of colorectal cancer among the African American patients in the study, and, specifically, high levels of antibodies to this protein were associated with colorectal cancer incidence in both African Americans and Asian Americans.

Meira Epplein, PhD, the lead author of the study, said, “The link between infection and cancer is intriguing, particularly if we can eradicate it with a simple round of antibiotics. Our study provides strong evidence that we need to pursue these studies to establish a definitive cause-and-effect. It was surprising to find VacA antibodies increased the odds of colorectal cancer in African Americans and Asian Americans, and not in whites and Latinos.” The study was published on October 5, 2018, in the journal Gastroenterology.

Related Links:
Duke University Medical Center

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.